Published on in Vol 8, No 3 (2022): Jul-Sep
Preprints (earlier versions) of this paper are
available at
https://preprints.jmir.org/preprint/39068, first published
.
![Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review](https://asset.jmir.pub/assets/7f83327105cd2640f767bf58bf85f27d.png 480w,https://asset.jmir.pub/assets/7f83327105cd2640f767bf58bf85f27d.png 960w,https://asset.jmir.pub/assets/7f83327105cd2640f767bf58bf85f27d.png 1920w,https://asset.jmir.pub/assets/7f83327105cd2640f767bf58bf85f27d.png 2500w)
1 RTI Health Solutions, Manchester, United Kingdom
2 SpringWorks Therapeutics, Stamford, CT, United States
3 Pfizer Inc, Groton, CT, United States
4 Pfizer Pharma GmbH, Berlin, Germany
*all authors contributed equally